These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22891198)

  • 1. Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers.
    Hu H; Zhang H; Ge W; Liu X; Loera S; Chu P; Chen H; Peng J; Zhou L; Yu S; Yuan Y; Zhang S; Lai L; Yen Y; Zheng S
    Clin Cancer Res; 2012 Oct; 18(19):5438-48. PubMed ID: 22891198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPARCL1 expression increases with preoperative radiation therapy and predicts better survival in rectal cancer patients.
    Kotti A; Holmqvist A; Albertsson M; Sun XF
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1196-202. PubMed ID: 24661672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.
    Li P; Qian J; Yu G; Chen Y; Liu K; Li J; Wang J
    J Surg Oncol; 2012 Jan; 105(1):31-7. PubMed ID: 22161898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.
    Kahlert C; Lahes S; Radhakrishnan P; Dutta S; Mogler C; Herpel E; Brand K; Steinert G; Schneider M; Mollenhauer M; Reissfelder C; Klupp F; Fritzmann J; Wunder C; Benner A; Kloor M; Huth C; Contin P; Ulrich A; Koch M; Weitz J
    Clin Cancer Res; 2011 Dec; 17(24):7654-63. PubMed ID: 22042972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma.
    Yu Y; Chen Y; Ma J; Yu X; Yu G; Li Z
    Tumour Biol; 2016 Mar; 37(3):4159-67. PubMed ID: 26490986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.
    Shen C; Yin Y; Chen H; Wang R; Yin X; Cai Z; Zhang B; Chen Z; Zhou Z
    BMC Gastroenterol; 2018 Jul; 18(1):105. PubMed ID: 29973149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.
    Hurley PJ; Hughes RM; Simons BW; Huang J; Miller RM; Shinder B; Haffner MC; Esopi D; Kimura Y; Jabbari J; Ross AE; Erho N; Vergara IA; Faraj SF; Davicioni E; Netto GJ; Yegnasubramanian S; An SS; Schaeffer EM
    Cancer Res; 2015 Oct; 75(20):4322-34. PubMed ID: 26294211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.
    Zhang HP; Wu J; Liu ZF; Gao JW; Li SY
    Biomed Res Int; 2022; 2022():1398268. PubMed ID: 35111844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
    Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
    Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis.
    Hu H; Cai W; Zheng S; Ge W
    Cell Physiol Biochem; 2017; 44(4):1485-1496. PubMed ID: 29190626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPARCL1 suppresses metastasis in prostate cancer.
    Xiang Y; Qiu Q; Jiang M; Jin R; Lehmann BD; Strand DW; Jovanovic B; DeGraff DJ; Zheng Y; Yousif DA; Simmons CQ; Case TC; Yi J; Cates JM; Virostko J; He X; Jin X; Hayward SW; Matusik RJ; George AL; Yi Y
    Mol Oncol; 2013 Dec; 7(6):1019-30. PubMed ID: 23916135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.
    Hurley PJ; Marchionni L; Simons BW; Ross AE; Peskoe SB; Miller RM; Erho N; Vergara IA; Ghadessi M; Huang Z; Gurel B; Park BH; Davicioni E; Jenkins RB; Platz EA; Berman DM; Schaeffer EM
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):14977-82. PubMed ID: 22927397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological significance of reduced SPARCL1 expression in human breast cancer.
    Cao F; Wang K; Zhu R; Hu YW; Fang WZ; Ding HZ
    Asian Pac J Cancer Prev; 2013; 14(1):195-200. PubMed ID: 23534723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.
    Gray MJ; Van Buren G; Dallas NA; Xia L; Wang X; Yang AD; Somcio RJ; Lin YG; Lim S; Fan F; Mangala LS; Arumugam T; Logsdon CD; Lopez-Berestein G; Sood AK; Ellis LM
    J Natl Cancer Inst; 2008 Jan; 100(2):109-20. PubMed ID: 18182619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPARCL1 suppresses cell migration and invasion in renal cell carcinoma.
    Ye H; Wang WG; Cao J; Hu XC
    Mol Med Rep; 2017 Nov; 16(5):7784-7790. PubMed ID: 28944877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex.
    Zhao SJ; Jiang YQ; Xu NW; Li Q; Zhang Q; Wang SY; Li J; Wang YH; Zhang YL; Jiang SH; Wang YJ; Huang YJ; Zhang XX; Tian GA; Zhang CC; Lv YY; Dai M; Liu F; Zhang R; Zhou D; Zhang ZG
    Oncogene; 2018 Feb; 37(8):1049-1061. PubMed ID: 29084211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial cell-derived fibronectin extra domain A promotes colorectal cancer metastasis via inducing epithelial-mesenchymal transition.
    Ou J; Peng Y; Deng J; Miao H; Zhou J; Zha L; Zhou R; Yu L; Shi H; Liang H
    Carcinogenesis; 2014 Jul; 35(7):1661-70. PubMed ID: 24743511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPARCL1 impedes trophoblast migration and invasion by down-regulating ERK phosphorylation and AP-1 production and altering EMT-related molecule expression.
    Liu X; Zhao J; Luan X; Li S; Zhai J; Liu J; Du Y
    Placenta; 2020 Jan; 89():33-41. PubMed ID: 31675488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver.
    Kuniyasu H; Luo Y; Fujii K; Sasahira T; Moriwaka Y; Tatsumoto N; Sasaki T; Yamashita Y; Ohmori H
    Gut; 2010 Mar; 59(3):348-56. PubMed ID: 19828468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.
    Herynk MH; Stoeltzing O; Reinmuth N; Parikh NU; Abounader R; Laterra J; Radinsky R; Ellis LM; Gallick GE
    Cancer Res; 2003 Jun; 63(11):2990-6. PubMed ID: 12782608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.